Abeona Therapeutics (ABEO) director awarded 37,313 restricted shares vesting in 2027

Rhea-AI Filing Summary

Abeona Therapeutics director Michael Amoroso received a stock grant. On January 26, 2026, he was awarded 37,313 shares of Abeona Therapeutics common stock at a price of $0.00 per share as restricted stock. After this grant, he beneficially owned 217,779 shares directly. All of the restricted stock is scheduled to vest on January 26, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Amoroso Michael

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		37,313(1)	A	$0.00	217,779	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All of the restricted stock will vest on January 26, 2027.

	/s/ Michael Amoroso	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report for Michael Amoroso?

Abeona Therapeutics reported that director Michael Amoroso received 37,313 shares of common stock as a restricted stock grant. The shares were awarded on January 26, 2026 at a price of $0.00 per share, increasing his direct beneficial ownership to 217,779 shares.

When do Michael Amoroso’s newly granted Abeona Therapeutics (ABEO) shares vest?

All 37,313 shares of restricted stock granted to director Michael Amoroso vest on January 26, 2027. Until that vesting date, the shares are subject to the restrictions described, after which they become fully vested common stock if conditions are satisfied.

How many Abeona Therapeutics (ABEO) shares does Michael Amoroso own after this Form 4?

Following the reported transaction, director Michael Amoroso beneficially owns 217,779 shares of Abeona Therapeutics common stock directly. This total reflects the addition of the 37,313 restricted shares granted on January 26, 2026 at a price of $0.00 per share.

What was the price of the Abeona Therapeutics (ABEO) shares granted to Michael Amoroso?

The 37,313 shares of Abeona Therapeutics common stock granted to director Michael Amoroso carried a transaction price of $0.00 per share. This indicates a compensatory restricted stock award rather than an open market purchase or sale at a prevailing trading price.

What type of security did Michael Amoroso receive from Abeona Therapeutics (ABEO)?

Michael Amoroso received restricted shares of Abeona Therapeutics common stock. The Form 4 reports a grant of 37,313 common shares at $0.00 per share, with all of this restricted stock scheduled to vest on January 26, 2027, subject to the applicable conditions.

Is Michael Amoroso a director or officer at Abeona Therapeutics (ABEO)?

The filing identifies Michael Amoroso as a director of Abeona Therapeutics. He is not indicated as a company officer or 10% owner in the report. The Form 4 reflects his role as a director receiving a restricted stock grant as part of his compensation.